Cannformatics, a biotechnology firm based in San Francisco, has made a groundbreaking discovery in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD). Their research, published in Nature’s Scientific Reports, showcases the use of Cannabis-Responsive (C-Res) biomarkers and machine learning to develop personalized therapies for ASD and other neurological conditions such as Alzheimer’s Disease, Multiple Sclerosis, and PTSD.
The study conducted by Cannformatics introduces an innovative approach that utilizes C-Res biomarkers to differentiate ASD patients based on metabolic imbalances. This breakthrough paves the way for tailored treatments beyond medical cannabis. Dr. Itzhak Kurek, CEO and co-founder of Cannformatics, highlights the potential impact of C-Res biomarkers in identifying metabolic imbalances in children with autism.
With their focus on introducing a saliva-based lab testing service, Cannformatics aims to empower healthcare providers and patients to customize and evaluate cannabis-based treatments with precision. Through their research, the company discovered that C-Res biomarkers can serve as a probe to identify metabolic imbalances in children with ASD. They hope to positively impact patients with neurological and neuropsychiatric conditions by understanding the mechanisms of action and metabolic pathways underlying THC, CBD, CBG, and other phytochemicals.
Preliminary results from Cannformatics’ research indicate that machine learning can effectively identify cannabinoid mechanisms and the entourage effects of phytochemicals, streamlining the development of effective therapies. The company’s study also sheds light on the therapeutic role of non-cannabinoid phytochemicals, such as terpenes, flavonoids, and phytosterols, in ASD treatment, demonstrating the entourage effect.
Cannformatics specializes in Cannabis-Responsive biomarkers for personalized cannabis treatment and product development. The first phase of their research, focused on ASD, is expected to launch within six months after the completion of the company’s Series-A fundraising round.
Kenneth Epstein, CCO and co-founder of Cannformatics, emphasizes the significance of their rigorously peer-reviewed data in validating the medical benefits and safety of cannabis. This breakthrough discovery opens doors for improved treatments for ASD and various neurological conditions, bringing hope to patients and their families worldwide.
